ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 530,72
0,00%
Dow Jones
39 164,06
0,09%
DAX
18 210,55
0,26%
Brent Oil
85,715
0,35%
Bitcoin
61 513,12
-0,16%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Arvinas Inc (ARVN)

  7. Arvinas Inc (ARVN) Actualités

ARVN Arvinas Inc

25,60
-0,27 (-1,04%)
28 Juin 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Arvinas Inc ARVN NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,27 -1,04% 25,60 01:59:35
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
25,83 25,08 26,10 25,85 25,87
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
24/6/202422:37GLOBEArvinas Appoints Andrew Saik as Chief Financial Officer and..
21/6/202413:00GLOBEArvinas Announces Presentations for Two of its PROTAC®..
18/6/202423:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/6/202423:51EDGAR2Form 3 - Initial statement of beneficial ownership of..
18/6/202422:55EDGAR2Form 8-K - Current report
17/6/202413:03EDGAR2Form 8-K - Current report
17/6/202413:00GLOBEArvinas Announces Promotions of Ian Taylor, Ph.D. to..
03/6/202422:30GLOBEArvinas to Participate in Upcoming Investor Conferences
31/5/202423:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/5/202422:52EDGAR2Form 8-K - Current report
24/5/202403:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/5/202423:00GLOBEArvinas Announces Upcoming Presentations at the 2024..
16/5/202412:05EDGAR2Form 8-K - Current report
16/5/202412:00GLOBEArvinas and Pfizer Announce Updated Clinical Data from Phase..
09/5/202422:42GLOBEArvinas Announces Upcoming Vepdegestrant Poster..
07/5/202422:13EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/5/202413:02EDGAR2Form 8-K - Current report
07/5/202413:00GLOBEArvinas Reports First Quarter 2024 Financial Results and..
02/5/202413:00GLOBEArvinas to Present at Upcoming Investor Conferences
24/4/202422:30GLOBEArvinas Appoints Randy Teel, Ph.D., as Chief Business..
11/4/202413:00GLOBEArvinas Enters into a Transaction with Novartis, including a..
18/3/202421:40GLOBEArvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief..
04/3/202413:00GLOBEArvinas to Participate in Upcoming Investor Conferences
28/2/202400:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202400:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202400:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202400:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202422:46EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27/2/202413:02EDGAR2Form 8-K - Current report
27/2/202413:00GLOBEArvinas Reports Fourth Quarter and Full Year 2023 Financial..
20/2/202422:06EDGAR2Form 8-K - Current report
20/2/202422:05GLOBEArvinas Announces Chief Financial Officer Transition
20/2/202413:00GLOBEArvinas Announces First-in-Human Dosing of ARV-102, an..
14/2/202414:00GLOBECarrick Therapeutics Announces First Patient Dosed in Phase..
14/2/202402:14EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06/2/202412:45GLOBEArvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA..
01/2/202422:30GLOBEArvinas to Present at 6th Annual Guggenheim Biotechnology..
16/1/202423:01GLOBEArvinas Appoints Jared Freedberg as General Counsel
16/1/202422:03EDGAR2Form S-8 - Securities to be offered to employees in employee..
08/1/202422:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202413:45EDGAR2Form 8-K - Current report
08/12/202315:16EDGAR2Form S-3ASR - Automatic shelf registration statement of..
06/12/202313:01EDGAR2Form 8-K - Current report
06/12/202304:52GLOBEArvinas to Host Conference Call and Webcast to Discuss..
05/12/202319:33GLOBEArvinas and Pfizer Announce Interim Data from Phase 1b Trial..
28/11/202323:05GLOBEArvinas and Pfizer Announce Updated Vepdegestrant (ARV-471)..
27/11/202313:11EDGAR2Form 8-K - Current report
27/11/202313:00GLOBEArvinas Announces Oversubscribed $350 Million Private..
07/11/202323:24EDGAR2Form S-3ASR - Automatic shelf registration statement of..
07/11/202322:27EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Dernières Valeurs Consultées

NASDAQ
ARVN
Arvinas
BIT
P20SE5
NLBNPIT20SE5 20240920 24
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés